Oncology Central

Court invalidates patent for prostate cancer drug Zytiga®

Johnson & Johnson (NJ, USA) have recently announced that the District Court of New Jersey has issued a ruling that invalidates all claims to the US Patent No. 8,822,438 for the prostate cancer drug Zytiga® (abiraterone acetate). The patent infringement case was filed against several companies who have submitted FDA applications to market generic versions of the drug.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.